Actively Recruiting

Phase 4
Age: 19Years +
All Genders
NCT05418556

Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent

Led by Asan Medical Center · Updated on 2026-03-30

3944

Participants Needed

25

Research Sites

323 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Objectives: To assess the safety of tailored antiplatelet therapy (short DAPT followed by P2Y12 inhibitor alone strategy) in patients who received optimized DES implantation guided by intravascular imaging (IVUS or OCT) Hypothesis: Tailored antiplatelet strategy (short DAPT followed by P2Y12 inhibitor alone) is superior to conventional antiplatelet strategy in terms of clinically relevant bleeding and noninferior for ischemic composite adverse events in patients who received intravascular imaging-guided optimized DES implantation. (Optimized stent evaluated by on-site IVUS/OCT could act as an essential criterion for decision making for tailored antithrombotic strategy)

CONDITIONS

Official Title

Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent

Who Can Participate

Age: 19Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men or women aged 19 years or older
  • Typical chest pain or objective evidence of myocardial ischemia suitable for PCI
  • Significant new coronary artery lesions suitable for DES implantation
  • Patients who underwent optimized stent implantation guided by IVUS or OCT meeting specific imaging criteria
  • Patient or guardian agrees to study protocol, follow-up schedule, and provides informed written consent
Not Eligible

You will not qualify if you...

  • Bypass graft lesions
  • Lesions with expected impaired delivery of imaging catheters due to extreme angulation (≥90°), excessive tortuosity (≥ two 45° angles), or heavy calcification
  • In-stent restenosis
  • Hypersensitivity or contraindication to device materials including cobalt, chromium, nickel, platinum, tungsten, acrylic, and fluoro polymers
  • Persistent thrombocytopenia (platelet count <80,000/µL)
  • History of hemorrhagic stroke, intracranial hemorrhage, TIA, or ischemic stroke within past 6 months
  • Known intolerance or hypersensitivity to aspirin, clopidogrel, ticagrelor, or heparin
  • Requirement for long-term oral anticoagulants or cilostazol
  • Planned surgery requiring general anesthesia or stopping aspirin/ADP antagonist within 12 months after procedure
  • Diagnosis or treatment of cancer (other than superficial skin cancer) in past 3 years
  • Clinically significant abnormalities at screening that preclude safe study completion
  • History of liver cirrhosis (Child-Pugh B or C) or biliary tract obstruction
  • Life expectancy less than 1 year from any cause
  • Cardiogenic shock at index admission
  • Pregnancy or breastfeeding
  • Active bleeding or high risk for major bleeding (e.g., peptic ulcer disease, gastrointestinal pathology, malignancies with high bleeding risk)
  • Unwillingness or inability to comply with study procedures

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 25 locations

1

Bucheon Sejong Hospital

Bucheon-si, South Korea

Actively Recruiting

2

Dong-A University Hospital

Busan, South Korea

Actively Recruiting

3

Inje University Busan Paik Hospital

Busan, South Korea

Not Yet Recruiting

4

Kosin University Gospel Hospital

Busan, South Korea

Actively Recruiting

5

Gyeongsang National University Changwon Hospital

Changwon, South Korea

Actively Recruiting

6

Kangwon National University Hospital

Chuncheon, South Korea

Actively Recruiting

7

Chungbuk National University Hospital

Chungju, South Korea

Actively Recruiting

8

Daegu Catholic Univ Medical Center

Daegu, South Korea

Not Yet Recruiting

9

Keimyung University Dongsan Medical Center

Daegu, South Korea

Actively Recruiting

10

Kyungpook National University Hospital

Daegu, South Korea

Not Yet Recruiting

11

Veterans Hospital

Daegu, South Korea

Not Yet Recruiting

12

Gangneung Asan Hospital

Gangneung, South Korea

Actively Recruiting

13

Jeonbuk National University Hospital

Jeonju, South Korea

Actively Recruiting

14

Gyeongsang National University Hospital

Jinju, South Korea

Actively Recruiting

15

Chungnam National University Sejong Hospital

Jungnam, South Korea

Actively Recruiting

16

Dankook University Hospital

Jungnam, South Korea

Actively Recruiting

17

Asan Medical Center

Seoul, South Korea

Actively Recruiting

18

Kangbuk Samsung Hospital

Seoul, South Korea

Actively Recruiting

19

Korea University Anam Hospital

Seoul, South Korea

Actively Recruiting

20

The Catholic University of Korea, Eunpyeong St. Mary's Hospital

Seoul, South Korea

Not Yet Recruiting

21

Veterans Hospital Service Medical Center

Seoul, South Korea

Actively Recruiting

22

Ajou University Hospital

Suwon, South Korea

Actively Recruiting

23

The Catholic University of Korea, ST. Vincent's Hospital

Suwon, South Korea

Completed

24

Ulsan University Hospital

Ulsan, South Korea

Actively Recruiting

25

Pusan National University Yangsan Hospital

Yangsan, South Korea

Not Yet Recruiting

Loading map...

Research Team

J

Ji Sue Hong, RN

CONTACT

P

Pil Hyung Lee, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here